Treatment of Bulimia Nervosa With Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 2: Improvement in Psychiatric Measures
The DOI matches its Crossref record.
Abstract
Article AbstractBackground: We conducted a 10-week, randomized, double-blind, placebo-controlled trial to examine the efficacy of topiramate in the treatment of bulimia nervosa. Primary efficacy analyses showed that topiramate treatment significantly reduced days on which patients binged and/or purged. This article describes further analyses investigating topiramate's effect on psychological symptoms associated with disordered eating. Method: Patients with DSM-IV bulimia nervosa were randomly assigned to receive topiramate (N = 35) or placebo (N = 34) for 10 weeks. Topiramate treatment was started at 25 mg/day and titrated by 25 to 50 mg/week to a maximum of 400 mg/day. Secondary psychiatric endpoints, including the Eating Disorder Inventory (EDI), Eating Attitudes Test (EAT), Hamilton Rating Scale for Anxiety (HAM-A), Hamilton Rating Scale for Depression (HAM-D), and Patient Global Improvement (PGI) were assessed for change from baseline in the topiramate versus placebo group. Results: Thirty-one patients receiving topiramate and 33 receiving placebo were included in the intent-to-treat analysis. Percent change from baseline on the EDI indicated significantly greater improvement in the topiramate group compared with the placebo group for subscales measuring bulimia/uncontrollable overeating (p = .005), body dissatisfaction (p = .007), and drive for thinness (p = .002). The EAT showed significant improvement in the topiramate group compared with the placebo group for the bulimia/food preoccupation (p = .019) and dieting (p = .031) subscales and the total score (p = .022). For the topiramate group, the reduction in mean HAM-A score was significantly greater (p = .046) than that in the placebo group, while reduction in HAM-D scores was greater in the topiramate group compared with the placebo group but did not reach statistical significance (p = .069). Significantly more patients treated with topiramate compared with placebo reported improvement on the PGI (p = .004). Conclusion: Topiramate treatment improves multiple behavioral dimensions of bulimia nervosa. Binge and purge behaviors are reduced, and treatment is associated with improvements in self-esteem, eating attitudes, anxiety, and body image. These results support topiramate as a viable therapeutic option for the treatment of bulimia nervosa. Additional, longer-term multicenter trials are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treasure, J., Claudino, A. M., & Zucker, N. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61748-7 · Cited by 658
Bulimia nervosa treatment: A systematic review of randomized controlled trials
Shapiro, J. R., Berkman, N. D., Brownley, K. A., Sedway, J. A., Lohr, K. N., & Bulik, C. M. (2007) · International Journal of Eating Disorders · doi:10.1002/eat.20372 · Cited by 630
Aigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
“Hedges et al. (2003) analysed the same sample and reported that there was also signifi cant reduction in other behavioural und psychopathological dimensions.”
BackgroundPsychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Metadata
- Authors
- Hedges, D. W., Reimherr, F. W., Hoopes, S. P., Rosenthal, N. R., Kamin, M., Karim, R., & Capece, J. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-12-15
- Volume
- 64
- Issue
- 12
- Pages
- 1449-1454
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W4252454142
- Cited by
- 104
- References
- 0
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Bulimia Nervosa With Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 2: Improvement in Psychiatric Measures. https://app.cochat.ai/papers/10.4088/jcp.v64n1208
- The paper
- Hedges, D. W., Reimherr, F. W., Hoopes, S. P., Rosenthal, N. R., Kamin, M., Karim, R., & Capece, J. A. (2003). Treatment of Bulimia Nervosa With Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 2: Improvement in Psychiatric Measures. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n1208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.